|
 The Anglo-Swedish drugmaker, which completed its $39 billion
purchase of rare disease drugs maker Alexion in July, has a large
portfolio of treatments for cancer, heart disease, diabetes and a
COVID-19 vaccine, with several drugs under trials.
"The future manufacturing of APIs for our medicines includes
compounds with highly complex synthesis ... This significant
investment will ensure the AstraZeneca supply network is fit for the
future," said Pam Cheng, head of AstraZeneca's operations and IT.
[to top of second column] |
 The planned investment in
Dublin is expected to support late-stage
development and early commercial supply, the
company said, adding that the site can be
developed further to add treatments such as
antibody drug conjugates and oligonucleotides.
(Reporting by Pushkala Aripaka in Bengaluru;
Editing by Arun Koyyur and Saumyadeb Chakrabarty)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
